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Edited by Wolfgang PetiClass A serine β-lactamases (SBLs) are key antibiotic resis-
tance determinants in Gram-negative bacteria. SBLs neutralize
β-lactams via a hydrolytically labile covalent acyl–enzyme in-
termediate. Klebsiella pneumoniae carbapenemase (KPC) is a
widespread SBL that hydrolyzes carbapenems, the most potent
β-lactams; known KPC variants differ in turnover of expanded-
spectrum oxyimino-cephalosporins (ESOCs), for example,
cefotaxime and ceftazidime. Here, we compare ESOC hydro-
lysis by the parent enzyme KPC-2 and its clinically observed
double variant (P104R/V240G) KPC-4. Kinetic analyses show
that KPC-2 hydrolyzes cefotaxime more efficiently than the
bulkier ceftazidime, with improved ESOC turnover by KPC-4
resulting from enhanced turnover (kcat), rather than altered
KM values. High-resolution crystal structures of ESOC acyl–
enzyme complexes with deacylation-deficient (E166Q) KPC-2
and KPC-4 mutants show that ceftazidime acylation causes
rearrangement of three loops; the Ω, 240, and 270 loops, which
border the active site. However, these rearrangements are less
pronounced in the KPC-4 than the KPC-2 ceftazidime acyl-
enzyme and are not observed in the KPC-2:cefotaxime acyl-
enzyme. Molecular dynamics simulations of KPC:ceftazidime
acyl-enyzmes reveal that the deacylation general base E166,
located on the Ω loop, adopts two distinct conformations in
KPC-2, either pointing “in” or “out” of the active site; with only
the "in" form compatible with deacylation. The "out" confor-
mation was not sampled in the KPC-4 acyl-enzyme, indicating
that efficient ESOC breakdown is dependent upon the ordering
and conformation of the KPC Ω loop. The results explain how
point mutations expand the activity spectrum of the clinically
important KPC SBLs to include ESOCs through their effects on
the conformational dynamics of the acyl–enzyme intermediate.This article contains supporting information.
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BY license (http://creativecommons.org/licenses/by/4.0/).Increasing antimicrobial resistance threatens global public
health (1), exemplified by resistance to β-lactams (e.g. carba-
penems and cephalosporins), the most prescribed antibiotics
worldwide (2). Cephalosporins, first introduced in the 1960s,
remain among the most widely used antibiotics, with dozens of
compounds differing in their substituents and antimicrobial
properties (3). Resistance to cephalosporins and other β-lac-
tams in Gram-negative bacteria (GNB) is predominantly
mediated by production of β-lactamases (1), which catalyze
hydrolysis of the β-lactam ring, rendering the antibiotic inac-
tive. β-Lactamases are divided into four groups based on
sequence and mechanism (4–6): classes A, C, and D are active-
site serine enzymes (serine β-lactamases [SBLs]) that hydrolyze
β-lactams via a covalent acyl–enzyme intermediate, whereas
class B metallo-β-lactamases use zinc cofactors (6). Carbape-
nems are the most recently introduced β-lactam antibiotic
class, with potent activity toward GNB, and inhibit many SBLs
through formation of long-lived and hydrolytically inert acyl-
enzymes (2, 7). However, their increasing use has resulted in
the emergence of carbapenemases, β-lactamases that hydro-
lyze carbapenems, threatening their continued clinical efficacy
(8, 9). Indeed, carbapenem-resistant Enterobacteriaceae and
Acinetobacter spp. were identified by the Centers for Disease
Control and Prevention as one of five urgent antibiotic resis-
tance threats (10).
Klebsiella pneumoniae carbapenemase-2 (KPC-2), a class A
SBL, was isolated from a carbapenem-resistant K. pneumoniae
strain collected in 1996 (11). Sequence variants were discov-
ered soon after (12, 13), and KPC family members have now
been identified on multiple mobile genetic elements, enabling
dissemination in numerous pathogenic GNB, such as Escher-
ichia coli, Pseudomonas aeruginosa (14), Klebsiella spp., and
Acinetobacter spp. (15). Unlike extended-spectrum class A β-
lactamases (ESBLs) such as CTX-M-15 (16), KPC-2 is capable
of hydrolyzing almost all β-lactam antibiotics, including car-
bapenems and most cephalosporins (17). The endemic status
of KPC SBLs worldwide, together with their hydrolytic activityJ. Biol. Chem. (2021) 296 100126 1
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KPC variants affect catalysis via acyl–enzyme dynamicsagainst a broad spectrum of β-lactams, makes this enzyme
family a leading cause of carbapenem and other β-lactam
failure in health care–associated infections. The KPC family
now comprises up to 54 distinct enzymes (18) representing
various insertions, deletions, and substitutions.
The parent enzyme, KPC-2, efficiently hydrolyzes penicil-
lins, cephalosporins, and carbapenems but poorly hydrolyzes
the expanded-spectrum oxyimino-cephalosporin (ESOC),
ceftazidime, particularly compared with the structurally
similar cefotaxime (Fig. 1) (13, 17). Cefotaxime and ceftazi-
dime feature a C7 oxyimino substituent (Fig. 1), hindering
binding and turnover by narrow-spectrum SBLs, such as SHV-
1 and TEM-1 (19, 20), and demonstrate broad-spectrum ac-
tivity against Gram-positive and Gram-negative aerobic and
anaerobic bacteria (21, 22). Ceftazidime, for example, is an
effective treatment for infections by organisms including
E. coli, K. pneumoniae, and P. aeruginosa (22). Compared with
cefotaxime, ceftazidime has a more complex, bulkier, C7
substituent with an additional carboxylate and two methyl
groups and is consequently poorly accommodated by the
active sites of most SBLs, including carbapenemases such as
KPC-2. Consistent with this, for most SBLs that turn over
ceftazidime, steady-state KM values are in the high micromolar
to millimolar range (17, 23–25). Ceftazidime is now combined
with the SBL inhibitor avibactam (Avycaz (26) or Zavicefta
(27)) to bolster clinical efficacy against resistant SBL pro-
ducers, particularly Enterobacteriaceae and drug-resistant
P. aeruginosa (26, 27). Avycaz has been approved to treat
bacterial pneumonia and complicated urinary tract and intra-
abdominal infections (26, 27).
KPC variants are the focus of increasing attention, partic-
ularly with respect to activity towards ceftazidime. The most
comprehensive study to date investigated the activity and
stability of the natural KPC variants 2 to 11 that possess single-
or double-point mutations at four positions (M49I, P104R,Figure 1. Structure and reaction of β-lactam antibiotics. A, acylation of cep
chain oxyimino groups are colored purple (methoxyimino for cefotaxime) an
(pyridinium for ceftazidime) or (acetoxy for cefotaxime) are colored pink.
2 J. Biol. Chem. (2021) 296 100126P104L, V240G, V240A, and H274Y; Table S1 (13)). This
identified differences in ceftazidime hydrolysis, with the vari-
ants KPC-4 (P104R and V240G substitutions) and KPC-10
(P104R and H274Y) exhibiting 50- and 75-fold increases in
kcat/KM compared with KPC-2, resulting in 32- and 42-fold
increases in the ceftazidime minimal inhibitory concentra-
tion when the respective variants are expressed in recombinant
E. coli (13). A reduction in thermodynamic stability of these
variants further indicated that increased ceftazidime hydrolysis
may be at a stability cost (13). Avycaz resistance, which
appeared soon after its first clinical use in 2015, is linked to the
emergence of KPC variants, some of which are thought to
impact ceftazidime kinetics (28–30).
Despite recent structural characterization of KPC enzymes,
including several complexes with inhibitors (31, 32) and two
with antibiotic hydrolysis products (33), their interactions with
substrates are not well understood. In particular, the absence
of structures for any acyl–enzyme complexes limits explana-
tion of their unusually broad spectrum of activity, and of how
naturally occurring point variants tune activity toward
different substrates (13). Here we describe investigations of
ESOC turnover by KPC-2 and its doubly substituted variant
KPC-4 that seek to understand the basis for the enhanced
ceftazidime turnover, and consequent ceftazidime resistance of
producer bacteria, by the latter. Crystal structures of the cef-
tazidime and cefotaxime acyl-enzymes of KPC-2, and the
ceftazidime acyl-enzyme of KPC-4, identify that KPC-2 un-
dergoes more extensive rearrangement on ceftazidime acyla-
tion than does KPC-4; extended molecular dynamics (MD)
simulations of the acyl–enzyme complexes identify a confor-
mation of the Ω loop, favored in KPC-2, that orients E166, the
general base for deacylation, away from the acyl–enzyme
carbonyl, restricting deacylation. These results highlight the
mobility of loops within and around the KPC active-site pocket
and the importance of this to hydrolysis of the ESOC substratehalosporins. B and C, structures of cefotaxime and ceftazidime. The C7 side
d teal (2-carboxypropan-2-yloxyimino for ceftazidime). C3’ leaving groups
Table 1
Steady-state parameters for cephalosporin hydrolysis by KPC-2 and
KPC-4
Substrate Kinetic parameter KPC-2 KPC-4
Ceftazidime kcat (s
−1) 1.9 (0.12) 81 (7.6)
KM (μM) 530 (70) 640 (110)
kcat/KM (μM
−1 s−1) 0.0035 (5.2 × 10−4) 0.13 (0.025)
Cefotaxime kcat (s
−1) 76 (6.6) 262 (32)
KM (μM) 200 (29) 190 (49)
kcat/KM (μM
−1 s−1) 0.38 (0.064) 1.37 (0.039)
Nitrocefin kcat (s
−1) 610 (9) 170 (44)
KM (μM) 18 (5) 59 (20)
kcat/KM (μM
−1 s−1) 34 (9.3) 3 (1.2)
KPC, Klebsiella pneumoniae carbapenemase.
Standard errors are provided in parentheses; n = 3; calculated in GraphPad Prism.
KPC variants affect catalysis via acyl–enzyme dynamicsceftazidime. Effecting alterations to the dynamic properties of
the acyl–enzyme intermediate then provides a mechanism by
which naturally occurring enzyme variants can modulate
specificity.
Results
V240G and P104R substitutions in KPC-4 improve turnover of
oxyimino-cephalosporins
To investigate activity differences between the naturally
occurring KPC variants KPC-2 and KPC-4 (P104R:V240G), we
first determined steady-state kinetic parameters for their hy-
drolysis of the oxyimino-cephalosporins ceftazidime and cefo-
taxime as well as the reporter substrate nitrocefin (34) (Table 1).
Consistent with previous reports of increased catalytic effi-
ciency (kcat/KM) for ceftazidime hydrolysis by some KPC var-
iants (13), we observe a 40-fold increase of kcat/KM for KPC-4
compared with KPC-2. Ceftazidime KM values are similarly
high for both variants (530 μM for KPC-2 and 640 μM for
KPC-4), the turnover rate increases 40-fold (kcat 1.9 s
−1 for
KPC-2 and 81 s−1 for KPC-4). The improved efficiency of
ceftazidime hydrolysis by KPC-4 can therefore be attributed to
changes in turnover, rather than KM. The two KPC variants also
differ in their turnover of other cephalosporins (cefotaxime and
nitrocefin). For cefotaxime, a substrate resembling ceftazidime,
but with a smaller C7 group (Fig. 1), KM values are lower than
those for ceftazidime for both KPC-2 and KPC-4 (200 and
190 μM, respectively) and kcat values substantially faster (76 and
262 s−1), resulting in KPC-4 ~fourfold more efficiently hydro-
lyzing cefotaxime than KPC-2 (kcat/KM 1.37 μM
−1 s−1 compared
with 0.38 μM−1 s−1). Conversely, for nitrocefin, a nonclinical
reporter substrate (34) similar to earlier cephalosporins, kcat/KM
for KPC-2 is tenfold higher than for KPC-4 (34 μM−1 s−1 and
3 μM−1 s−1, respectively) reflecting differences in Michaelis
constant (KM = 18 and 59 μM, respectively) and turnover rate
(kcat = 610 and 170 s
−1, respectively). Thus, compared with
KPC-2, the P104R/V240G double substitutions in KPC-4
selectively improve activity against bulkier ESOCs through ac-
celeration of turnover rate (kcat).
Deacylation-deficient KPC-2 and KPC-4 mutants yield crystal
structures of cephalosporin acyl-enzymes
To further study the basis for KPC activity against the
ESOCs cefotaxime and ceftazidime, deacylation-deficientmutants of KPC-2 and KPC-4 were generated by conserva-
tive substitution of the general base E166 (35) with the isos-
teric residue Gln (KPC-2E166Q and KPC-4E166Q). Exposure of
both KPC-2E166Q and KPC-4E166Q crystals to cephalosporins
allowed trapping of the respective acyl-enzymes. We obtained
high-resolution crystal structures of the acyl-enzymes of KPC-
2E166Q with both ceftazidime and cefotaxime (resolution of
1.25 and 1.31 Å, respectively) and of KPC-4E166Q with cefta-
zidime (resolution of 1.24 Å). Data collection and refinement
statistics are presented in Table 2. Clear Fo − Fc difference
density in the KPC active sites allowed confident modeling of
the Ser70 acyl-enzymes, with ligand real-space correlation
coefficients >0.95 (Fig. S1 and Table S2). Uninterrupted
polypeptide chains starting at residue 23 (KPC-2E166Q,
KPC-2E166Q:ceftazidime, and KPC-4E166Q:ceftazidime) or 25
(KPC-4E166Q and KPC-2E166Q:cefotaxime) to residue 294 were
built into the experimental electron density for all structures
except KPC-2E166Q:ceftazidime, for which residues 166 to 172
and 270 to 274 were not well resolved.
We also determined structures of uncomplexed KPC-
2E166Q (resolution of 1.30 Å) and KPC-4E166Q (resolution of
1.40 Å), confirming that mutation at position 166 does not
induce substantial changes in the overall fold of the native
enzyme (KPC-2 Protein Data Bank [PDB] 5UL8 (33), root-
mean-square deviation [RMSD] = 0.157 Å and KPC-4
6QWE (31), RMSD = 0.201 Å for KPC-2E166Q and KPC-
4E166Q, respectively; Fig. S2 and Table S3). There are few
differences between the active sites of KPC-2 and KPC-
2E166Q. The hydrogen bond networks, observed in most class
A SBL structures, which involve S70, K73, S130, E166,
N170 and an active-site water molecule in the putative
deacylating position (labeled DW; Fig. S2 and Table S4),
remain unperturbed. In KPC-4, however, a small change in
the position of Q166 (compared with E166 in the unmodified
enzyme) results in repositioning (by 2.4 Å) of the putative
deacylating water. The positions of other active-site residues
are identical to those observed in native KPC-4 (Fig. S2B and
Table S4).
Ceftazidime is bound in one clearly resolved conformation
in the KPC-2E166Q acyl–enzyme complex and was refined at
full occupancy (Fig. S1A). However, in KPC-4E166Q, the 2-
carboxypropan-2-yloxyimino group of the ceftazidime C7
substituent (Fig. 1B; teal) was modeled in two conformations:
major (A, 75% occupancy) and minor (B, 25% occupancy) in
which the orientations of the carboxylate and methyl groups
differ by 180 (Fig. S1B and Table S2). Similarly, cefotaxime
was refined in complex with KPC-2E166Q in two conformations
(A, 49% and B, 51%; Fig. S1C and Table S2) that differ largely
through a 180 rotation of the oxyimino group and amino-
thiazole ring of the C7 substituent. This is associated with
movement of the cephem dihydrothiazine ring, which shifts to
prevent a clash with the reoriented aminothiazole ring in
conformation A (Figs. 2C and S1C). The electron density of all
three KPC acyl-enzymes was not observed for the C3 sub-
stituents (Fig. S1), indicating that the 3’ pyridinium (ceftazi-
dime) groups or acetoxy (cefotaxime) groups have been
efficiently eliminated after acylation to give a C3 exomethyleneJ. Biol. Chem. (2021) 296 100126 3
Table 2
Crystallographic data collection and refinement statistics
Dataset KPC-2E166Q KPC-2E166Q:cefotaxime KPC-2E166Q:ceftazidime KPC-4E166Q KPC-4E166Q:ceftazidime
PDB ID 6Z21 6Z23 6Z24 6Z22 6Z25
Data collection
Beamline DLS I24 ALBA XALOC-BL-13 DLS I04 DLS I04 DLS I04
Space group P21212 P21212 P21212 P21212 P21212
Molecules/ASU 1 1 1 1 1
Cell dimensions
a, b, c (Å) 60.20, 78.44, 55.96 60.14, 78.91, 55.65 60.27, 77.21, 55.41 60.20, 78.94, 55.98 60.23, 77.26, 55.74
α, β, γ () 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90
Resolution (Å) 45.56–1.30 (1.32–1.30) 45.48–1.31 (1.33–1.31) 77.21–1.25 (1.27–1.25) 45.66–1.40 (1.42–1.40) 55.74–1.24 (1.26–1.24)
Rpim 0.034 (0.686) 0.028 (0.770) 0.028 (0.315) 0.052 (0.696) 0.038 (0.828)
CC1/2 0.999 (0.460) 0.999 (0.638) 0.999 (0.833) 0.999 (0.674) 0.999 (0.747)
I/σ (I) 11.8 (0.9) 12.4 (0.9) 14.5 (2.2) 8.8 (1.3) 9.4 (1.0)
Completeness (%) 100 (100) 100 (100) 99.2 (98.0) 100 (100) 98.6 (97.0)
Redundancy 12.6 (12.2) 12.6 (13.1) 12.9 (12.4) 13.4 (12.3) 13.8 (14.3)
Refinement
Resolution (Å) 32.86–1.30 45.48–1.31 55.41–1.25 45.66–1.40 55.571–1.24
No. of reflections 65,793 64,287 71,368 53,103 73,046
Rwork/Rfree 0.143/0.173 0.1601/0.1792 0.1497/0.1798 0.1417/0.1763 0.1453/0.1704
No. of atoms
Protein 2087 2133 2029 2063 2132
Solvent 279 251 285 337 294
Ligand — 52 31 — 62
B-factors (Å2)
Protein 22 24 16 20 18
Solvent 41 45 37 35 38
Ligand — 32 17 — 23
RMSD
Bond lengths (Å) 0.008 0.009 0.011 0.007 0.010
Bond angles () 0.982 1.063 1.389 0.954 1.141
Ramachandran (%)
Outliers 0.00 0.00 0.00 0.00 0.00
Favoured 98.9 98.48 98.81 98.5 98.5
ASU, asymmetric unit; DLS, Diamond Light Source; ID, identity; KPC, Klebsiella pneumoniae carbapenemase; PDB, Protein Data Bank; RMSD, root-mean-square deviation.
Values in parentheses represent information from the highest resolution shells.
KPC variants affect catalysis via acyl–enzyme dynamicsgroup, consistent with observations of other cephalospor-
in:SBL acyl-enzymes (36–39).
Ceftazidime binding induces large structural changes in KPC-2
On reaction with KPC-2E166Q, ceftazidime induces relatively
large global changes (Cα RMSD = 0.618 Å compared with apo
KPC-2E166Q; Table S3). In particular, the Ω loop (residuesFigure 2. Oxyimino-cephalosporin acyl–enzyme complexes with KPC-2E1
cefotaxime as pink sticks. The secondary structure is displayed as a cartoon, for
incomplete or poor electron density are flanked by yellow spheres represent
cefotaxime and ceftazidime within the KPC-2E166Q and KPC-4E166Q active sites.
spheres, and distances as dashes. KPC, Klebsiella pneumoniae carbapenemase.
4 J. Biol. Chem. (2021) 296 100126165–170) and residues 270 to 274 (henceforth referred to as
the 270 loop) are highly disordered, as evidenced by a lack of
interpretable electron density (Figs. 3 and S3). Ω Loop
restructuring appears necessary to prevent significant steric
clashes of N170 with the aminothiazole ring of the C7 sub-
stituent (Fig. 2). Although residues 239 to 243 (the 240 loop)
manifest well-defined experimental electron density (B-66Q and KPC-4E166Q. Ceftazidime is represented as green cyan sticks and
KPC-2E166Q in gray and KPC-4E166Q in teal. Regions not modeled because of
ing the Cα atoms of the last residue modeled. A, B, and C, interactions of
Key amino acids are highlighted as pale blue sticks, water molecules as red
Figure 3. Variable organisation of loops surrounding the active sites of
KPC acyl-enzymes. A, conformational changes in the Ω, 240, and 270 loops
(labeled) are manifest in superimpositions of KPC-2E166Q (red), KPC-4E166Q
(blue), KPC-2E166Q:cefotaxime (pink), KPC-2E166Q:ceftazidime (gray), and KPC-
4E166Q:ceftazidime (teal). The beginning and end of disordered regions in
the KPC-2E166Q:ceftazidime crystal structures are represented as yellow
spheres, and the corresponding residues numbered in the KPC-2E166Q and
KPC-4E166Q structures. B, the open and closed conformations of the Ω loop
in KPCE166Q acyl–enzyme complexes, colored as in A. DW, water molecule in
the putative deacylating position; KPC, Klebsiella pneumoniae
carbapenemase.
KPC variants affect catalysis via acyl–enzyme dynamicsfactor = 18.6 Å2), they move considerably, relative to their
positions in the apoenzyme, that is, away from the Ω loop and
toward the position of the 270 loop in uncomplexed KPC-2
(Figs. 2 and 3 and S2). The reasons for this substantialchange in the position of the 240 loop are unclear, but could
reflect the proximity of the flexible/disordered Ω loop, the
binding mode of the ceftazidime aminothiazole ring, and/or
the provision of hydrophobic interactions between V240 and
the methyl groups of the ceftazidime C7 substituent (closest
distance between CH3 groups is 4.5 Å). This movement of the
240 loop, and the consequent potential for steric clashes, can
additionally explain the absence of electron density for the 270
loop.
Ceftazidime binding to KPC-4E166Q (i.e. KPC-2E166Q P104R/
V240G) induces notably less pronounced conformational
changes, with Cα RMSDs of 0.269/0.254 Å compared with
unliganded KPC-4E166Q or KPC-2E166Q, respectively
(Table S3). Indeed, for the KPC-4E166Q: ceftazidime acyl-
enzyme, the 240 loop (containing the V240G substitution) and
the 270 loop are both well defined by the electron density (B-
factors 15.78 and 20.0 Å2, respectively) and occupy similar
positions to those in the unliganded KPC-4E166Q/KPC-2E166Q
and KPC-2/KPC-4 structure. However, although the complete
Ω loop could be modeled in relatively weak electron density
(all atom B-factors for residues 165–175 are more than twice
those of the remainder of the main chain [43.79 versus 18 Å2]),
a likely consequence of the amino group of the ceftazidime C7
aminothiazole ring being directed out of the active site
(Figs. 2B and 4C and S3), it adopts an open conformation
compared with its position in the unmodified enzyme (Fig. 3).
Thus, structural changes in the Ω loop are required for cef-
tazidime to bind to either KPC-2E166Q or KPC-4E166Q,
consistent with the high KM values for the native enzymes (530
and 640 μM; Table 1).
In contrast, cefotaxime binding to KPC-2E166Q causes
minimal structural changes compared with unmodified KPC-
2E166Q (Cα RMSD = 0.145 Å; Table S3). Furthermore, the Ω
loop, 240 loop, and 270 loop are all well defined by the electron
density (B-factors 28.8, 18.0, 27.9 Å2, respectively), and
conserved active-site residues all occupy similar positions to
those found in unmodified KPC-2 (33) and KPC-2E166Q, with
the deacylating water situated between N170 and Q166
(Fig. 2C and S2). Thus, although we note that overall KM
values for ESOC turnover (Table 1) reflect contributions from
the microscopic rate constants for multiple individual steps
along the hydrolysis pathway (40), and that in consequence,
KM will be sensitive to changes in the structures and dynamics
of transient species as well as those of the acyl–enzyme state
observed here, our structural data therefore suggest that the
lower KM value for KPC-2–catalyzed cefotaxime, compared
with ceftazidime, hydrolysis may in part reflect the lack of a
requirement for significant active-site rearrangements in the
cefotaxime acyl-enzyme.
Interactions of the cephalosporin acyl-enzymes with the KPC
active site
Ceftazidime and cefotaxime make several hydrogen bonds
to the same active-site residues in KPC-2E166Q and KPC-4E166Q
(Fig. 2), reflecting their similar core structures. In all three
complexes, the oxyimino-cephalosporin C-8 (β-lactam)J. Biol. Chem. (2021) 296 100126 5
Figure 4. Conformations of cefotaxime and ceftazidime in KPC acyl-enzymes. A, conf B of KPC-2E166Q:cefotaxime (pink) and KPC-2E166Q:ceftazidime
(gray). B, conf B of KPC-2E166Q:cefotaxime (pink) and KPC-4E166Q:ceftazidime (teal). C, KPC-2E166Q:ceftazidime (gray) and KPC-4E166Q:ceftazidime (teal). Arrows
with a black outline represent positioning of the aminothiazole ring of the C7 side chain. Arrows with a blue outline highlight the position of the amine
group on the aminothiazole ring. KPC, Klebsiella pneumoniae carbapenemase.
KPC variants affect catalysis via acyl–enzyme dynamicscarbonyl oxygen binds in the oxyanion hole formed by the
backbone amides of S70 and T237 (35) (2.7 and 2.9–3.0 Å,
respectively), whereas the N5 (β-lactam) nitrogen hydrogen
bonds with the S130 side chain (2.8 Å). The C-4 carboxylate
makes weaker interactions with S130 (3.0–3.1 Å), and with the
backbone oxygen of T216 via a water molecule (Wat2) but
participates in stronger hydrogen bonds with the side chains of
T235 and T237. In all three KPC complexes, the N132 side
chain nitrogen points toward the C7 amide carbonyl oxygen
(3.0–3.1 Å).
The three structures differ in the positioning of the amino-
thiazole ring of the C7 substituent (Fig. 4). In particular, the
cefotaxime aminothiazole ring points away from the KPC-2
active site, toward C238 on the 240 loop, whereas in the cefta-
zidime acyl-enzymes, the ring is buried deeper within the active
site (Figs. 2 and 4). In both KPC-2 and KPC-4, the ceftazidime
aminothiazole ring is positioned where N170 typically resides in
the apoenzyme (Fig. S2), explaining why the Ω loop is reposi-
tioned in both complexes (to the point that it could not be
modeled in the KPC-2:ceftazidime complex; Fig. 3) and why in
KPC-4 N170 points into bulk solvent, away from the active site,
thus enlarging the active site to accommodate ceftazidime
(Fig. 2B). These changes to the KPC-4Ω loop likely cause Q166
to interact with a water molecule (WAT3) positioned 2.5 Å
above the water in the putative deacylating position (DW,
Fig. 2B). Furthermore, in KPC-2E166Q the ceftazidime amino-
thiazole amino group points towards the position of N170 in
unliganded KPC-2, whereas in KPC-4 the amino group instead
points away from the Ω loop and towards the 240 loop, likely
reflecting the reduced potential for steric clashes arising from
the V240G substitution (Fig. 4C).
The positions of P/R104 and W105 in KPC acyl-enzymes
Residues 104 and 105 (Fig. 5A), located adjacent to class A
SBL active site, have been implicated in discrimination6 J. Biol. Chem. (2021) 296 100126between substrates and stabilization of reaction intermediates,
as supported by studies of residue 105 across a range of en-
zymes (TEM-1 (41), KPC-2 (42, 43), and SME-1 (44), among
others (45, 46)). Here, we observe multiple conformations of
W105 (Fig. 5), as previously described in structures of unli-
ganded KPC enzymes from the P21212 crystal form (31, 33). In
the KPC-2E166Q:cefotaxime complex, W105 was modeled in
two conformations (Fig. 5B; occupancies 0.53 and 0.47),
similar to those observed in unliganded KPC-2 (33) (Fig. 5E).
This could reflect the possibility for hydrophobic interactions
between W105 and either the aminothiazole or dihy-
drothiazine rings. Conversely, in the KPC-2E166Q:ceftazidime
complex, W105 adopts a single conformation that is well
defined by the electron density, with the indole nitrogen
hydrogen bonding to the ceftazidime C7 carboxylate (3.2 Å;
Fig. 5C).
In KPC-4E166Q:ceftazidime (containing the P104R substitu-
tion), W105 adopts a conformation closer to that in apo KPC-
4E166Q (Fig. 5F) and KPC-2E166Q:cefotaxime (Fig. 5B), pointing
away from the bulky R104 and into the active site (Fig. 5D),
where it can make a hydrophobic interaction with the dihy-
drothiazine ring. R104 is directed toward ceftazidime, making
hydrogen bonds with the ceftazidime C7 side chain carbox-
ylate (conformation A = 2.8 Å and conformation B = 3.3 Å).
The orientation of W105 within the KPC active site is there-
fore both substrate dependent and influenced by the P104R
substitution in KPC-4.
KPC-2 demonstrates increased Ω loop flexibility, compared
with KPC-4, in MD simulations of the ceftazidime acyl-enzyme
To test the apparent conformational flexibility observed in
our crystal structures, as evidenced in both the KPC-
2E166Q:ceftazidime and KPC-4E166Q:ceftazidime acyl–enzyme
complexes by structural rearrangements and/or the absence
of experimental electron density, we undertook MD
KPC variants affect catalysis via acyl–enzyme dynamics
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and KPC-4. For these simulations, Q166 was replaced with
glutamate (E166) in the ceftazidime complexes to regenerate
the active enzyme in silico, and disordered regions of the
KPC-2E166Q:ceftazidime acyl-enzyme were manually built us-
ing restraints and the Modloop server (47) (minimized com-
plex shown in Fig. S4A). To investigate the effect of the E166Q
substitution on protein dynamics, we initially subjected the
eight complex/unliganded structures (KPC-2, KPC-4, KPC-
2E166Q, KPC-4E166Q, KPC-2:ceftazidime, KPC-4:ceftazidime,
KPC-2E166Q:ceftazidime, and KPC-4E166Q:ceftazidime) to
100 ns MD simulations in triplicate. Cα RMSDs of all residues
remained stable throughout 100 ns, and active-site residue
RMSDs were similar between E166 and Q166 structures
(Figs. S5 and S6). Therefore, as the Q166 and E166 structures
behaved similarly, we focused on the wildtype (i.e. E166) en-
zymes in subsequent 500 ns simulations (repeated in
triplicate).
Backbone (Cα) RMSD values remained stable throughout
500 ns (Fig. S7), with unliganded KPC-2 and KPC-4 overall
marginally more rigid than their respective ceftazidime acyl-
enzymes. By-residue root mean square fluctuation (RMSF)
analysis showed the Ω, 240, and 270 loops of both the KPC-2
and KPC-4:ceftazidime acyl–enzyme complexes to be more
mobile than the remainder of the protein, but, notably, this
enhanced mobility was not evident in unliganded KPC-2 or
KPC-4 (Fig. S8). Of the four systems studied, the KPC-
2:ceftazidime acyl-enzyme exhibited consistently higher
RMSF values across all three loops, reflecting the weak or
absent crystallographic electron density for these regions
(Figs. 2 and 3 and S3 and S8). Flexibility of the Ω loop is
manifest within 1 ns of MD equilibration in simulations of
both the KPC-2 and KPC-4 ceftazidime acyl-enzymes, and is
accompanied by movements of the ceftazidime C7 side chain
(Fig. S4). Visual inspection of the complete MD trajectories
revealed E166 (and the entire Ω loop) to be highly mobile in
simulations of both the KPC-2 and KPC-4 ceftazidime acyl-
enzymes, consistent with weak (KPC-4) or absent (KPC-2)
experimental electron density for this region. In particular, in
the KPC-2 acyl-enzyme, E166 adopted two distinct orienta-
tions (Fig. 6), either pointing “in” to the active site or “out” into
solvent where it is unable to interact with the deacylating water
molecule (DW) or with other components of the active-site. In
KPC-4, E166 adopted only the “in” conformation, although the
Ω loop still underwent movements during the simulations.
To identify favored conformations of ceftazidime, and
associated movements of the Ω loop, MD trajectories of
KPC-2:ceftazidime were investigated with cluster analysis
(48, 49). This identified distinct clusters relating to the “in” or
“out” positions of E166 and the orientation of the ceftazidime
C7 aminothiazole ring (Fig. S9). Three clusters are presentedFigure 5. Positioning of residues P/R104 and W105 in KPC crystal structure
105 are shown as sticks and labeled. Distances of potential interactions betw
overall KPC-2 fold (PDB 5UL8), showing positions of key active-site residues an
(gray), D, KPC-4E166Q:ceftazidime (teal), E, unliganded KPC-2 (pale blue) and KPC
the multiple conformations adopted by W105 in the various structures. DW, wa
carbapenemase; PDB, Protein Data Bank.
8 J. Biol. Chem. (2021) 296 100126in Figure S9. In the first, E166 points in (Fig. S9B), and the
C7 aminothiazole of bound ceftazidime is oriented as in the
crystal structure. In the second, the Ω loop and E166 move
out and away from the active site, but ceftazidime retains the
orientation observed in the first cluster (Fig. S9C). In the
third, there is a substantial change in the ceftazidime binding
mode as the aminothiazole ring occupies the space created
by the movement of the Ω loop that positions E166 in the
“out” conformation (Fig. S9D). To accompany these confor-
mational changes, P104 moves closer (from 6.7 Å after
2.5 ns to 3.5 Å after 422 ns of simulation) to the methyl
groups of the C7 oxyimino group, with which it can then
participate in van der Waals interactions. Despite these dif-
ferences, the acyl-enzyme β-lactam–derived C8 carbonyl re-
mains within the oxyanion hole for the entire simulation
(Fig. S10); this contrasts with previous studies of class A
enzymes with carbapenems that show that the carbapenem
carbonyl can flip out of the oxyanion hole (50–52). Equiva-
lent cluster analysis of MD trajectories for the KPC-
4:ceftazidime complex reveals that E166 is directed into the
active site in all clusters (Fig. S11), with the ceftazidime
aminothiazole oriented as in the crystal structure and the
acyl–enzyme carbonyl remaining in the oxyanion hole. There
are small movements of the R104 side chain, which in the
crystal structure hydrogen bonds to the C7 oxyimino group
carboxylate; this interaction between R104 and the carbox-
ylate (Fig. S12) is present in most simulations. Movements of
R104 during MD may therefore correlate with movements of
this C7 group, which throughout remains at hydrogen-
bonding distance (2.7–3.0 Å) to the arginine Nε and Nη
atoms (Figs. S11 and S12).
To quantify how often E166 points in or out of the active
site, the distance between the E166 Cδ and the Cα of the
nucleophilic S70 was monitored across all simulations. In
unliganded KPC-2 and KPC-4, the Ω loop remains stable, with
E166 directed into the active site in 100% of frames (Fig. S13),
and the distance between E166 and S70 remaining below 7 Å
(averaging 5.04 Å and 5.14 Å for KPC-2 and KPC-4, respec-
tively). In the KPC-4:ceftazidime acyl-enzyme, the average
E166 to S70 distance was 9.5 Å, with E166 pointing toward S70
in 100% of frames, reflecting the conformational change of
the Ω loop in the crystal structure into a more open state
(Figs. 3 and 6 and S14), similar to that in a CTX-M-
14:ceftazidime crystal structure (PDB 5TW6 (36)). In
contrast, in trajectories of the KPC-2:ceftazidime acyl-enzyme,
E166 is on average 15.17 Å from S70, with this distance
distributed between 12 and 18.6 Å in 98% of frames, i.e.,
E166 is predominantly directed out of the active site. E166 is
only within 11 Å of S70, and thus oriented in the in confor-
mation observed for KPC-4, in frames comprising <3% of the
trajectory (Fig. S14C).s. Cefotaxime/ceftazidime are represented as thick sticks. Residues 104 and
een 104/105 are highlighted as gray dashes. A, representative view of the
d loops (labeled). B, KPC-2E166Q:cefotaxime (pink), C, KPC-2E166Q:ceftazidime
-2E166Q (dark blue), and F, unliganded KPC-4 (pink) and KPC-4E166Q (red). Note
ter molecule in the putative deacylating position; KPC, Klebsiella pneumoniae
Figure 6. Conformations of E166 in KPC-2 and KPC-4 molecular dynamics trajectories. A, snapshots of KPC-2:ceftazidime acyl-enzyme identified by
cluster analysis, which represent "in" and "out" conformations of E166. 2.5 ns (gray) and 63.5 ns (pale pink). B, snapshots of KPC-4:ceftazidime acyl-enzyme
identified by cluster analysis, which represent movements of E166 pointing "in" to the active site. 38.1 ns (teal) and 420.4 ns (blue). In KPC-4:ceftazidime
simulations, E166 only samples "in" conformations. KPC, Klebsiella pneumoniae carbapenemase.
KPC variants affect catalysis via acyl–enzyme dynamicsDiscussion
The ESOC ceftazidime is a widely used antibiotic and rela-
tively poor substrate for the globally distributed KPC carba-
penemases. In recent years, KPC variants have emerged with
increased ceftazidime turnover. In particular, acquisition of two
substitutions in KPC-4, V240G, and P104R, results in a 40-/50-
fold increase in catalytic efficiency over the KPC-2 parent (13),
leading in producer strains to an increase in minimal inhibitory
concentration for ceftazidime (12, 13). Our steady-state kinetic
data show this to be due to increased turnover (kcat) rather than
changes in KM. Using deacylation-deficient mutants, we
captured high-resolution crystal structures of the KPC-2 and
KPC-4 ceftazidime acyl-enzymes, alongside the equivalent
complex of KPC-2 with cefotaxime, an ESOC with a smaller C7
side chain that is a better substrate. The combination of these
structures with MD simulations presents an explanation for
enhanced ceftazidime turnover by KPC-4. Such information is
of growing clinical relevance with the emergence of further
KPC variants and the likely increase in ceftazidime use (and
selection pressure), arising from clinical introduction of the
ceftazidime–avibactam combination (26).
KPC-4 turns over ceftazidime an order of magnitude more
efficiently than KPC-2 (kcat/KM values: 0.13 μM
−1 s−1 and
0.0035 μM−1 s−1, respectively). Our crystal structure of the
KPC-4:ceftazidime complex shows that both the P104R and
V240G substitutions affect ceftazidime binding and hydrolysis:
the former directly through interaction of R104 with the cef-
tazidime C7 carboxylate and indirectly by dictating positioning
of W105; the latter by enabling accommodation of the ami-
nothiazole ring with its amino substituent pointing away from
the Ω loop, maintaining E166 in an orientation compatible
with productive deacylation. Thus, although ceftazidime
binding to KPC-2 induces conformational changes in the 240,
270, andΩ loops, binding to KPC-4 did not alter positioning of
the 240 and 270 loops and involved less pronounced changes
to the Ω loop than in KPC-2. The conclusion that ceftazidime
binding is more disruptive to KPC-2 is supported by MD
simulations of the acyl-enzymes, which show the KPC-2 Ωloop to be more mobile and with E166 generally oriented away
from S70, in a conformation incompatible with its role acti-
vating the deacylating water. We conclude that the KPC-
2:ceftazidime acyl-enzyme predominantly adopts a conforma-
tion incompatible with E166-catalyzed hydrolysis, whereas the
KPC-4 acyl–enzyme conformation, specifically that of the Ω
loop, remains permissive for deacylation, with E166 and S70
consistently remaining in proximity. These findings are
consistent with the respective turnover numbers (ceftazidime
kcat values: 1.9 s
−1 and 81 s−1 for KPC-2 and KPC-4, respec-
tively), and the crystal structure of the KPC-2:cefotaxime acyl-
enzyme, where, in contrast to the above, the conformations of
the 240, 270, and Ω loops are little affected by binding of this
relatively good substrate (kcat = 76 s
−1 and KM = 200 μM). This
change in the respective populations of the "in" and "out"
conformations of E166 can account for the difference in ac-
tivity toward ceftazidime between KPC-2 and KPC-4.
Differences between the two KPC variants are less apparent
in MD simulations of the uncomplexed (apo) enzymes, with
increased mobility of the Ω loop only evident after ceftazidime
acylation. Furthermore, comparison with others’ MD data
suggests that different β-lactams cause different effects upon
KPC dynamics after acylation: the active-site loop bearing
W105, but not the 240, 270, or Ω loops, exhibits increased
mobility in the complex with the penam sulfone inhibitor PSR-
3-226 (53). W105 has also been identified as governing tran-
sitions between catalytically permissive (interacting with the
oxyanion hole) and nonpermissive (loss of oxyanion hole in-
teractions) conformations in simulations based upon models
(i.e. docked rather than crystallographically defined) of the
KPC-2:meropenem acyl-enzyme (52).
Our acyl–enzyme structures can also explain why various
KPC point variants, several of which are associated with clin-
ical failure of the ceftazidime:avibactam combination, display
altered activity toward ceftazidime. Substitutions characterized
in ceftazidime:avibactam-resistant strains include H274Y
(KPC-3 (13)); H274Y combined with deletion of residues 242
and 243 (KPC-28 (30)); V240G (28); T243M/A (28, 29); andJ. Biol. Chem. (2021) 296 100126 9
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within loops whose conformations are significantly affected by
ceftazidime binding, where repositioning of the 240 loop ne-
cessitates conformational changes in the 270 loop to avoid
steric clashes with the ceftazidime aminothiazole ring. From
our results, deletions or substitutions in the 240 loop are ex-
pected to reduce such clashes, specifically by better accom-
modating the ceftazidime aminothiazole ring. In this context,
we note that deletions in the 240 loop (KPC-28) substantially
lower ceftazidime KM values compared with both KPC-2 and
KPC-3. The H274Y substitution may further reduce the en-
ergetic burden associated with 240 loop reorganization. Sub-
stitutions, such as D179Y, in and around the Ω loop (which we
show to be highly mobile in both crystal structures and MD
simulations of the ceftazidime acyl-enzyme), probably aid
ceftazidime acylation by modifying Ω loop behavior and dy-
namics to favor acylation-competent conformations of E166.
The D179Y mutation may also affect the salt bridge between
D179 and R164 (a residue itself shown to be important to
ceftazidime turnover (17)).
Our results make possible comparisons of the mechanisms
by which different class A β-lactamases expand their activity
spectrum to encompass ESOCs, specifically ceftazidime. The
basis for ESOC hydrolysis by ESBLs has been extensively
studied in the TEM, SHV, and CTX-M SBL families, where
efficient turnover requires acquisition of point mutations by a
parent enzyme that lacks such activity (19, 57). In the TEM
family, the parent TEM-1 enzyme exhibits poor cefotaxime or
ceftazidime turnover and variants, such as R164S (19, 58),
E104K (19), or E240K (58) (also associated with activity against
ceftazidime in SHV enzymes (20)) enhance ceftazidime turn-
over. The first of these is proposed to increase conformational
heterogeneity of the Ω loop to better accommodate ceftazi-
dime (59), whereas E104K/E240K may participate in direct
interactions with ceftazidime (58). In the CTX-M ESBL family,
where the parent hydrolyzes cefotaxime efficiently but cefta-
zidime poorly, turnover of the latter is moderately improved by
point mutations such as P167S or D240G. These are proposed
to increase Ω loop flexibility to access a more open confor-
mation, improving accommodation of ceftazidime, while E166
remains in a deacylation-competent orientation (60). This
contrasts with KPC, in which our high-resolution crystal
structures and MD simulations indicate that greatly enhanced
ceftazidime turnover by KPC-4 (compared with KPC-2) is
instead associated with reduced flexibility, or increased sta-
bility, of the acyl-enzyme Ω loop, constraining E166 in an
orientation compatible with productive deacylation. This is
further highlighted by the KPC-2:cefotaxime acyl–enzyme
crystal structure in which the Ω loop is highly stable and
close to the unliganded conformation, rationalizing better
cefotaxime turnover in vitro.
Collectively, the results support the hypothesis that exten-
sion of activity toward expanded-spectrum cephalosporins,
specifically ceftazidime, through acquisition of point variants
by different class A β-lactamases, is associated with changes in
Ω loop dynamics and the sampling of acyl–enzyme confor-
mations that increase populations of deacylation-competent10 J. Biol. Chem. (2021) 296 100126states. However, despite the structural similarity between
class A β-lactamases, available data indicate that populated
acyl–enzyme conformations, and their associated hydrolytic
activities, vary between different SBLs. This is exemplified by
the apparently opposing effects of increasedΩ loop flexibility
upon ceftazidime hydrolysis in the CTX-M (36, 60) and KPC
enzyme families. These differences likely reflect differing
active-site structures and associated activity spectra of the
progenitor enzymes as well as differences in stability/dy-
namics of the overall enzyme structure. Our results reveal
that studies of acyl-enzymes and their reactivity are partic-
ularly important for understanding deacylation activity (61).
Molecular simulations have an important role to play in
characterizing the dynamics and activity of acyl-enzymes and
can potentially be used as computational assays of activity
(62). For example, likely activity would be indicated for acyl-
enzymes of KPC variants where simulations show E166
predominantly in “in” conformations, whereas lower deacy-
lation activity would be predicted from simulations showing
E166 further from the active site. Extension of simulations to
the quantum mechanics/molecular mechanics (QM/MM)
level could then enable a quantitative correlation between
populations of different conformations and turnover rates.
In conclusion, our determination of the first crystal struc-
tures of acyl-enzymes for the clinically important KPC enzyme
identifies how two point substitutions (P104R/V240G)
dramatically improve ceftazidime hydrolysis. Our data
demonstrate both the importance of Ω loop dynamics in
turnover of complex ESOC substrates, and the existence of a
trade-off between the Ω loop flexibility necessary to accom-
modate such antibiotics and the cost to catalytic efficiency of
the associated disruption to the active site, specifically with
respect to the orientation of the E166 general base and its
ability to participate in deacylation. Point mutations acquired
by KPC-4 resolve this conflict by modifying the conforma-
tional distribution of the ceftazidime acyl-enzyme to favor the
deacylation-competent orientation of E166. Our findings
therefore show how the spectrum of activity of KPC enzymes
is modified by variation and suggest that future cephalosporin
development can be aided by understanding conformational
dynamics during catalysis and taking into account enzyme–
substrate interactions involved in the evolution of resistance.
The approach described here should aid activity prediction for
variant enzymes, whereas the inactive acyl–enzyme con-
formers that we identify can potentially be targeted in β-lactam
development. Finally, our finding that a naturally selected KPC
variant alters specificity by affecting the structure and dy-
namics of the acyl-enzyme, rather than the ground (unli-
ganded) state, highlights the need to consider the effects on
reaction intermediates in studies of the evolution of β-lacta-
mase activity.Experimental procedures
Site-directed mutagenesis of the KPC variants
DNA encoding for KPC-2 and KPC-4 codons 25 to 293 were
cloned into pET28a (Noavagen). Deacylation-deficient
KPC variants affect catalysis via acyl–enzyme dynamics(E166Q) mutants were generated using primers 50-TCA GCT
CCA GCT GCC AGC GGT CCA G-30 and 50-CTG GAC CGC
TGG CAG CTG GAG CTG A-30 and the QuikChange II XL
lightening SiteDirected Mutagenesis Kit, according to the
manufacurer’s instructions (Agilent Genomics).
Protein crystallization, antibiotic soaking, and data collection
The KPC variants (KPC-2, KPC-4, KPC-2E166Q, and KPC-
4E166Q) were purified and crystallized as described previously
(31). For unliganded data sets of KPC-2E166Q and KPC-4E166Q,
crystals were soaked in mother liquor supplemented with 25%
glycerol before cryocooling in liquid nitrogen. KPC-2E166Q
crystals and KPC-4E166Q crystals were soaked in solutions of
30 mM ceftazidime (Merck) and KPC-2E166Q crystals in
20 mM cefotaxime (Merck). Antibiotic solutions were made in
mother liquor supplemented with 20% to 30% glycerol. Crys-
tals were soaked from 5 min to several hours; the best data sets
were collected at 3.5 h (KPC-2E166Q:ceftazidime), 2.5 h (KPC-
2E166Q:cefotaxime), and 30 min (KPC-4E166Q:ceftazidime).
Diffraction data were collected at Diamond Light Source
beamlines I03, I04, and I24 and ALBA beamline BL13 XALOC.
Images were indexed and integrated using Dials (63) in the
Xia2 pipeline (64) (Diamond Light Source data sets) or XDS
(65) (ALBA data) and subsequently scaled in AIMLESS (CCP4
suite (66)). Crystallographic phases were calculated in Phaser
(67) using PDB:5UL8 (33) (crystal structure of KPC-2) as a
molecular replacement solution. Initial refinements in
REFMAC 5 confirmed Fo–Fc electron density consistent with
bound ligand, before further rounds of refinement in phe-
nix.refine (68) and manual model building in Coot (69). Ge-
ometry restrains for antibiotics were calculated using eLBOW
in PHENIX, and omit maps were generated in PHENIX (68)
from the final model in the absence of the antibiotic. Ligand
occupancies were manually assigned based upon inspection of
electron density and subsequently refined in Phenix with at
least 10 rounds of refinement. Figures were generated in Pymol
(www.pymol.org) .
Enzyme assays
All enzyme assays were performed at 25 C in 10 mM
HEPES, pH 7.5, 150 mM NaCl in Greiner half area 96-well
plates, and a Tecan Infinite 200 pro microplate reader.
Steady-state kinetic parameters were calculated by measuring
β-lactam antibiotic hydrolysis (cefotaxime Δε262 = −7660 (17),
ceftazidime Δε265 = −7445, and nitrocefin Δε486 = 20,500 (31)).
Initial rates (V0) of β-lactam hydrolysis were plotted against
concentration of antibiotic; kinetic parameters were calculated
and analyzed using the Michaelis–Menten curve in GraphPad
Prism 6 (GraphPad Software, La Jolla, CA, USA; www.
graphpad.com).
MD simulations
The crystal structures of KPC-2 (PDB 5UL8), KPC-4 (PDB
6QWE), KPC-2E166Q, KPC-4 E166Q, KPC-2E166Q:ceftazidime,
and KPC-4E166Q:ceftazidime were used as starting structures
for molecular simulation. The unresolved regions of KPC-2E166Q:ceftazidime (because of poorly defined electron density)
were built in to the sparse electron density using both
KPC-4E166Q:ceftazidime and KPC-2E166Q:cefotaxime crystal
structures as a reference. MODELLER (ModLoop (47)) was
then used to predict loop conformations of the 165 to 170 and
the 270 to 274 regions. The resulting KPC-2E166Q:ceftazidime
structure and KPC-4E166Q:ceftazidime were used to model
the unmodified enzyme by mutating residues Q166 back to
wildtype E166 in WinCoot using the experimental electron
density. The resulting eight protein crystal structures (KPC-2,
KPC-4, KPC-2E166Q, KPC-4 E166Q, KPC-2E166Q:ceftazidime,
KPC-4E166Q:ceftazidime, KPC-2:ceftazidime, and KPC-
4:ceftazidime) were parameterized for molecular simulation.
All crystallographically observed water molecules were
included in the structures. Protonation states of titratable
residues were determined using the PropKA 3.1 server. In
tleap (AMBER16 (48)), hydrogens were added, and the systems
were solvated using a 10 Å water box (TIP4P) with overall
charges neutralized by addition of Na+ or Cl− atoms replacing
bulk water molecules. The ceftazidime acyl–enzyme parame-
ters were generated using the restrained electrostatic potential
fitting as implemented in the RED Server (70). All structures
underwent a standard minimization (600 of deepest descent
and 600 steps of conjugate gradient), heating (25 to 298 K in
20 ps), and equilibration MM MD (1 ns) protocol. The
structures were then simulated using MM MD in the
AMBER16 simulation package (48) using the ff14SB (71) MM
force field for protein, the TIP4P-Ew water model, and the
General AMBER Force Field (48). All eight protein systems
were simulated in triplicate runs for 100 ns, and KPC-2, KPC-
4, KPC-2:ceftazidime, and KPC-4:ceftazidime were further
simulated in triplicate runs of 500 ns. RMSD, RMSF, clus-
tering, and distance analyses were performed in CPPTRAJ in
AMBER16 (48). RMSD calculations were performed using the
first frame (1 ps) as the reference.Data availability
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